Indicated for: cancer
Route of administration: injectable
Substance: vinorelbine (antineoplastic agent)
ATC: L01CA04 (Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Vinca alkaloids and analogues)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Vinorelbine is a chemotherapy medication used for the treatment of various types of cancer, including non-small cell lung cancer and advanced breast cancer. It belongs to the vinca alkaloid class and works by inhibiting tubulin polymerization, which leads to the arrest of cell division and ultimately tumor cell death.
Vinorelbine is administered intravenously or orally, depending on the type and stage of cancer, and the dosage is adjusted based on body weight and patient response. Treatment is usually given in cycles to allow the body to recover between doses.
Common side effects include nausea, vomiting, fatigue, alopecia, and myelosuppression (reduction in blood cell counts). In rare cases, severe adverse reactions such as peripheral neuropathy or liver function impairment may occur.
Patients receiving vinorelbine should be regularly monitored for hematologic function and signs of toxicity. The medication is an important option in cancer treatment, helping to reduce tumor size and prolong patient survival.